• 1
    Inturrisi CE, Max MB, Foley KM, Schultz M, Shin S-U, Houde RW. The pharmacokinetics of heroin in patients with chronic pain. New Engl. J. Med. 1984; 310: 121317.
  • 2
    Boerner V, Abbot S, Roe RL. The metabolism of morphine and heroin in man. Drug Metab. Rev. 1975; 4: 3973.
  • 3
    Lockridge O, Mattershaw-Jackson N, Eckerson HW, LaDu BN. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J. Pharmacol. Exp. Ther. 1980; 215: 18.
  • 4
    Kamendulis LM, Brezezinski MR, Pindel EV, Bosron WF, Dean RA. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J. Pharmacol. Exp. Ther. 1996; 279: 71317.
  • 5
    Smith DA & Cole WJ. Identification of an arylesterase as the enzyme hydrolysing diacetylmorphine (heroin) in human plasma. Biochem. Pharmacol. 1976; 25: 36770.
  • 6
    Owen JA & Nakatsu K. Diacetylmorphine (heroin) hydrolases in human blood. Can. J. Physiol. Pharmacol. 1983; 61: 8705.
  • 7
    Ben Aziz-Aloya R, Seidman S, Timberg R, Sternfeld M, Zakut H, Soreq H. Expression of a human acetylcholinesterase promoter-reporter construct in developing neuromuscular junctions of Xenopus embryos. Proc. Natl Acad. Sci. USA 1993; 90: 24715.
  • 8
    Inturrisi CE, Schultz M, Shin S, Umans JG, Angel C, Simon EJ. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci. 1983; 33: 7736.
  • 9
    Barrett DA, Dyssegaard AL, Shaw PN. The effect of temperature and pH on the deacylation of diamorphine in aqueous solution and in human plasma. J. Pharm. Pharmacol. 1992; 44: 6068.
  • 10
    Liao J, Mortensen V, Norgaard-Pedersen B, Koch C, Brodbeck U. Monoclonal antibodies against brain acetylcholinesterase which recognize the subunits bearing the hydrophobic anchor. Eur. J. Biochem. 1993; 215: 3340.
  • 11
    Ellman GL, Courtney D, Anders VJr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961; 7: 8895.
  • 12
    Schwarz M, Loewenstein-Lichtenstein Y, Glick D, Liao J, Norgaard-Pedersen B, Soreq H. Successive organophosphate inhibition and oxime reaction reveals distinct responses of recombinant human cholinesterase variants. Mol. Brain Res. 1995; 31: 10110.
  • 13
    Loewenstein-Lichtenstein Y, Schwarz M, Glick D, Soreq H. Genetic predisposition to adverse consequences of anti-cholinesterases in ‘atypical’ BCHE carriers. Nature Med. 1995; 1: 10825.
  • 14
    Martin WR & Fraser HF. A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in post-addicts. J. Pharmacol. Exp. Ther. 1961; 133: 38899.
  • 15
    Nakamura G, Thornton JI, Noguchi TT. Kinetics of heroin deacylation in aqueous alkaline solution and in human serum and whole blood. J. Chromatogr. 1975; 110: 819.
  • 16
    Neville LF, Gnatt A, Loewenstein Y, Seidman S, Ehrlich G, Soreq H. Intramolecular relationships in cholinesterases revealed by oocyte expression of site-directed and natural variants of human BCHE. EMBO J. 1992; 11: 16419.
  • 17
    Soreq H, Ben-Aziz R, Prody CA et al. Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G+C-rich attenuating structure. Proc. Natl Acad. Sci. USA 1990; 87: 968892.
  • 18
    Sussman JL, Harel M, Frolow F et al. Atomic structure of acetylcholinesterase from Torpedo californica: A prototype acetylcholine binding protein. Science 1991; 253: 8729.
  • 19
    Taylor P & Radic Z. The cholinesterases: From genes to proteins. Ann. Rev. Pharmacol. Toxicol. 1994; 34: 281320.
  • 20
    Shafferman A, Velan B, Ordentlich A et al. Substrate inhibition of acetylcholinesterase: Residues affecting signal transduction from the surface to the catalytic center. EMBO J. 1992; 11: 36518.
  • 21
    Cauet G, Friboulet A, Thomas D. Horse serum butyrylcholinesterase kinetics: A molecular mechanism based on inhibition studies with dalensylaminoethyltrimethylammonium. Biochem. Cell. Biol. 1987; 65: 52935.
  • 22
    Eriksson H & Agustinsson KB. A mechanistic model for butyrylcholinesterase. Biochim. Biophys. Acta 1979; 567: 16173.
  • 23
    Getley SJ. Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochem. Pharmacol. 1991; 41: 124954.
  • 24
    Haas R, Adams EW, Rosenberry MA, Rosenberry TL. Substrate-selective inhibition and peripheral site labeling of acetylcholinesterase by platinum (terpyridine) chloride. In: Shafferman A, Velan B (eds). Multidisciplinary Approaches to Cholinesterase Functions. Plenum Press, New York. 1992; 131–9.